Matthew Collin

Matthew Collin has advanced understanding of FLT3 ligand (FLT3L) as a critical growth factor for dendritic cell expansion and its therapeutic potential in cancer immunotherapy, demonstrating that FLT3L administration dramatically increases circulating DC numbers and enhances anti-tumor immune responses. His work on human DC development and the effects of FLT3L on DC subset expansion has guided clinical trial design. He has contributed to understanding DC deficiencies in cancer patients and their reconstitution. His research supports FLT3L as an adjunct to DC-based and checkpoint immunotherapy.